Cover Image
市場調查報告書

骨質疏鬆症市場·預測分析

Osteoporosis Market and Forecast Analysis

出版商 Datamonitor Healthcare 商品編碼 498958
出版日期 內容資訊 英文 230 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
骨質疏鬆症市場·預測分析 Osteoporosis Market and Forecast Analysis
出版日期: 2018年03月09日 內容資訊: 英文 230 Pages
簡介

本報告提供骨質疏鬆症的已上市藥物及開發平台趨勢,彙整疾病概要,地區/各主要國家的患者數的變化與預測,主要的已上市藥物簡介,開發平台趨勢等資料。

流行病學:骨質疏鬆症

  • 摘要整理
  • 疾病的背景
  • 資訊來源·調查手法
  • 預測:骨質缺乏症
  • 預測:骨質疏鬆症
  • 流行病學者的考察
  • 優勢·規定
  • 附錄

已上市藥物:骨質疏鬆症

  • 摘要整理
  • 產品概要
  • 雙磷酸鹽
  • 雌激素·SERM
  • 抑鈣素
  • 其他藥劑級
  • 產品簡介: Forteo
  • 產品簡介: Prolia

開發平台:骨質疏鬆症

  • 摘要整理
  • 臨床實驗平台:概要
  • 比較儀治療
  • 近幾年中止的藥物
  • 產品簡介 (後期): Evenity
  • 產品簡介 (後期): abaloparatide

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4728

DISEASE OVERVIEW

Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures. Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease. It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture.

MARKET SNAPSHOT

Prolia will drive growth of the US market, while Forteo losses will halt growth in Japan and the EU.

The oral bisphosphonate alendronate dominates the treatment of all severities of low bone mass.

Forecasted growth in the total prevalence of osteopenia and osteoporosis will be driven by aging populations.

Biosimilar erosion and new anabolic entrants with superior efficacy are set to erode Forteo's blockbuster sales.

The arrival of Amgen's Evenity will be delayed due to safety issues.

CONTENTS

 

10 FORECAST: OSTEOPOROSIS (Published on 31 May 2017)

10 OVERVIEW

11 EXECUTIVE SUMMARY

12 MARKET OVERVIEW AND TRENDS

29 MARKET DEFINITION AND METHODOLOGY

36 ACTONEL (RISEDRONATE)

41 BONIVA (IBANDRONATE)

46 DUAVEE ([CONJUGATED ESTROGENS + BAZEDOXIFENE])

49 EDIROL (ELDECALCITOL)

53 EVENITY (ROMOSOZUMAB)

56 EVISTA (RALOXIFENE)

59 FORTEO (TERIPARATIDE) AND MOVYMIA (TERIPARATIDE)

66 FOSAMAX (ALENDRONATE)

71 PROLIA (DENOSUMAB)

77 RECLAST (ZOLEDRONIC ACID)

80 TYMLOS (ABALOPARATIDE)

84 PRIMARY RESEARCH METHODOLOGY

86 TREATMENT: OSTEOPOROSIS (Published on 23 March 2017)

86 OVERVIEW

87 EXECUTIVE SUMMARY

88 PRIMARY RESEARCH METHODOLOGY

91 DISEASE DEFINITION AND DIAGNOSIS

97 PATIENT SEGMENTATION

98 CURRENT TREATMENT OPTIONS

101 PRESCRIBING TRENDS

103 TREATMENT TRENDS IN OSTEOPENIA

109 TREATMENT TRENDS IN OSTEOPOROSIS

116 TREATMENT TRENDS IN SEVERE OSTEOPOROSIS

120 COMPLIANCE RATES

121 UNMET NEEDS IN OSTEOPOROSIS

122 EPIDEMIOLOGY: OSTEOPOROSIS (Published on 23 February 2017)

122 OVERVIEW

123 EXECUTIVE SUMMARY

124 DISEASE BACKGROUND

126 SOURCES AND METHODOLOGY

134 FORECAST: OSTEOPENIA

143 FORECAST: OSTEOPOROSIS

152 EPIDEMIOLOGIST INSIGHT

158 STRENGTHS AND LIMITATIONS

160 APPENDIX: ADDITIONAL SOURCES

161 MARKETED DRUGS: OSTEOPOROSIS (Published on 09 March 2018)

161 OVERVIEW

162 PRODUCT OVERVIEW

163 BISPHOSPHONATES

166 ESTROGENS AND SERMS

169 CALCITONIN

171 ANABOLIC THERAPIES

172 OTHER DRUG CLASSES

173 PRODUCT PROFILE: FORTEO

186 PRODUCT PROFILE: PROLIA

197 PRODUCT PROFILE: TYMLOS

207 PIPELINE: OSTEOPOROSIS (Published on 09 March 2018)

207 OVERVIEW

208 CLINICAL PIPELINE OVERVIEW

209 COMPARATOR THERAPY

214 RECENTLY DISCONTINUED DRUGS

218 PRODUCT PROFILE (LATE STAGE): EVENITY

LIST OF FIGURES

  • 12 Figure 1: Osteoporosis drug sales across the US, Japan, and five major EU markets, by country, 2016-25
  • 14 Figure 2: Osteoporosis sales in the US, by class, 2016-25
  • 18 Figure 3: Osteoporosis sales for Edirol, generic eldecalcitol, Forteo, and Evenity in Japan, by product, 2016-25
  • 26 Figure 4: Osteoporosis sales for Forteo, Movymia, biosimilar teriparatide, Evenity, and Tymlos across the US, Japan, and five major EU markets, 2016-25
  • 27 Figure 5: Osteoporosis sales for branded and generic bisphosphonates across the US, Japan, and five major EU markets, 2016-25
  • 31 Figure 6: Patient-based forecast methodology for osteoporosis
  • 33 Figure 7: Price sources and calculations, by country
  • 37 Figure 8: Actonel sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 39 Figure 9: Generic risedronate sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 42 Figure 10: Boniva sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 44 Figure 11: Generic ibandronate sales for osteoporosis across the US, Germany, Italy, Spain, and the UK, by country, 2016-25
  • 47 Figure 12: Duavee sales for osteoporosis across the US and Italy, by country, 2016-25
  • 50 Figure 13: Edirol sales for osteoporosis in Japan, 2016-25
  • 51 Figure 14: Generic eldecalcitol sales for osteoporosis in Japan, 2016-25
  • 54 Figure 15: Evenity sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 57 Figure 16: Evista sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 60 Figure 17: Forteo sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 62 Figure 18: Movymia sales for osteoporosis across the five major EU markets, by country, 2016-25
  • 64 Figure 19: Biosimilar teriparatide sales for osteoporosis in the US, 2016-25
  • 67 Figure 20: Fosamax sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 69 Figure 21: Generic alendronate sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 72 Figure 22: Prolia sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 74 Figure 23: Biosimilar denosumab sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 78 Figure 24: Reclast sales for osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 81 Figure 25: Tymlos sales for osteoporosis across the US and five major EU markets, by country, 2016-25
  • 94 Figure 26: Percentage of patients with low bone mass diagnosed at each disease subtype for the US, Japan, and five major EU markets
  • 97 Figure 27: Segmentation of patients suffering from low bone mass in the US, Japan, and five major EU markets, by disease severity and country
  • 102 Figure 28: Percentage of patients receiving each line of therapy, by severity
  • 103 Figure 29: Percentage of diagnosed patients receiving each type of therapy for the treatment of osteopenia, by country
  • 104 Figure 30: Percentage of diagnosed patients receiving each class of pharmacological therapy for the first-line treatment of osteopenia, by country
  • 105 Figure 31: Top three first-line treatment regimens for osteopenia patients, by country
  • 109 Figure 32: Percentage of diagnosed patients receiving each type of therapy for the treatment of osteoporosis, by country
  • 111 Figure 33: Percentage of diagnosed patients receiving each class of pharmacological therapy for the first-line treatment of osteoporosis, by country
  • 112 Figure 34: Top three first-line treatment regimens for osteoporosis patients, by country
  • 113 Figure 35: Top three second-line treatment regimens for osteoporosis patients, by country
  • 114 Figure 36: Top three third-line treatment regimens for osteoporosis patients, by country
  • 116 Figure 37: Top three first-line treatment regimens for severe osteoporosis patients, by country
  • 118 Figure 38: Top three second-line treatment regimens for severe osteoporosis patients, by country
  • 119 Figure 39: Percentage of diagnosed patients receiving each class of pharmacological therapy for the third-line treatment of severe osteoporosis, by country
  • 120 Figure 40: Compliance rates of patients suffering from low bone mass in the US, Japan, and five major EU markets, by country and disease subtype
  • 121 Figure 41: Key unmet needs in osteoporosis treatment across the US, Japan, and five major EU markets
  • 138 Figure 42: Trend in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
  • 139 Figure 43: Absolute change in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
  • 147 Figure 44: Trend in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
  • 148 Figure 45: Absolute change in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
  • 153 Figure 46: Age-specific growth in total prevalent cases of osteopenia in the US, Japan, and five major EU markets, 2016-36
  • 154 Figure 47: Age-specific growth in total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, 2016-36
  • 180 Figure 48: Forteo for osteoporosis - SWOT analysis
  • 181 Figure 49: Datamonitor Healthcare's drug assessment summary of Forteo for osteoporosis
  • 182 Figure 50: Datamonitor Healthcare's drug assessment summary of Forteo for osteoporosis
  • 191 Figure 51: Prolia for osteoporosis - SWOT analysis
  • 192 Figure 52: Datamonitor Healthcare's drug assessment summary of Prolia for osteoporosis
  • 193 Figure 53: Datamonitor Healthcare's drug assessment summary of Prolia for osteoporosis
  • 201 Figure 54: Tymlos for osteoporosis - SWOT analysis
  • 202 Figure 55: Datamonitor Healthcare's drug assessment summary of Tymlos for osteoporosis
  • 203 Figure 56: Datamonitor Healthcare's drug assessment summary of Tymlos for osteoporosis
  • 223 Figure 57: Evenity for osteoporosis - SWOT analysis
  • 224 Figure 58: Datamonitor Healthcare's drug assessment summary of Evenity for osteoporosis
  • 225 Figure 59: Datamonitor Healthcare's drug assessment summary of Evenity for osteoporosis

LIST OF TABLES

  • 13 Table 1: Osteoporosis drug sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 15 Table 2: Osteoporosis sales in the US, by brand and class ($m), 2016-25
  • 19 Table 3: Osteoporosis sales in Japan, by brand and class ($m), 2016-25
  • 22 Table 4: Osteoporosis sales in the five major EU markets, by brand and class ($m), 2016-25
  • 30 Table 5: Summary of drug classes and molecules in Datamonitor Healthcare's osteoporosis patient-based forecast
  • 34 Table 6: Exchange rates used for calculating prices
  • 34 Table 7: Patent expiry dates for key marketed brands in osteoporosis across the US, Japan, and five major EU markets, by country, 2016-25
  • 35 Table 8: Estimated launch dates for key late-stage osteoporosis pipeline candidates in the US, Japan, and five major EU markets, by country, 2016-25
  • 38 Table 9: Actonel sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 40 Table 10: Generic risedronate sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 43 Table 11: Boniva sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 45 Table 12: Generic ibandronate sales for osteoporosis across the US, Germany, Italy, Spain, and the UK, by country ($m), 2016-25
  • 47 Table 13: Duavee sales for osteoporosis across the US and Italy, by country ($m), 2016-25
  • 50 Table 14: Edirol sales for osteoporosis in Japan ($m), 2016-25
  • 51 Table 15: Generic eldecalcitol sales for osteoporosis in Japan ($m), 2016-25
  • 55 Table 16: Evenity sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 58 Table 17: Evista sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 61 Table 18: Forteo sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 63 Table 19: Movymia sales for osteoporosis across the five major EU markets, by country ($m), 2016-25
  • 64 Table 20: Biosimilar teriparatide sales for osteoporosis in the US ($m), 2016-25
  • 68 Table 21: Fosamax sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 70 Table 22: Generic alendronate sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 73 Table 23: Prolia sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 75 Table 24: Biosimilar denosumab sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 79 Table 25: Reclast sales for osteoporosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 82 Table 26: Tymlos sales for osteoporosis across the US and five major EU markets, by country ($m), 2016-25
  • 84 Table 27: Physicians surveyed for the osteoporosis primary research study, 2016
  • 88 Table 28: Physicians surveyed for the osteoporosis primary research study, 2016
  • 91 Table 29: World Health Organization definitions of bone mass based on BMD
  • 93 Table 30: Clinical risk factors included in FRAX scoring
  • 98 Table 31: Selected bisphosphonates products for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • 99 Table 32: Selected SERMs and estrogen products for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • 99 Table 33: Calcitonin products for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • 100 Table 34: Other drugs available for the treatment of osteoporosis across the US, Japan, and five major EU markets
  • 101 Table 35: Low bone mass patients treated with pharmacological therapy in the US, Japan, and five major EU markets, by country (%)
  • 107 Table 36: Top three third-line treatment regimens for osteopenia patients, by country (%)
  • 127 Table 37: Sources used for the epidemiological analysis of osteopenia and osteoporosis in the US, Japan, and five major EU markets, by country
  • 129 Table 38: Sources not used for the epidemiological analysis of osteopenia and osteoporosis in the US, Japan, and five major EU markets, by country
  • 135 Table 39: Total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016-36
  • 140 Table 40: Age-specific total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016
  • 141 Table 41: Gender-specific total prevalent cases of osteopenia in the US, Japan, and five major EU markets, by country, 2016
  • 144 Table 42: Total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016-36
  • 149 Table 43: Age-specific total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016
  • 150 Table 44: Gender-specific total prevalent cases of osteoporosis in the US, Japan, and five major EU markets, by country, 2016
  • 162 Table 45: Key marketed drugs for osteoporosis
  • 163 Table 46: Bisphosphonate class overview
  • 166 Table 47: Estrogens/SERMs class overview
  • 169 Table 48: Salmon calcitonin class overview
  • 171 Table 49: Anabolic class overview
  • 172 Table 50: Other drug classes overview
  • 173 Table 51: Forteo drug profile
  • 175 Table 52: Forteo pivotal trial data in osteoporosis
  • 178 Table 53: Forteo late-phase trial data in osteoporosis
  • 186 Table 54: Prolia drug profile
  • 188 Table 55: Prolia pivotal trial data in osteoporosis
  • 190 Table 56: Prolia late-phase trial data in osteoporosis
  • 198 Table 57: Tymlos drug profile
  • 199 Table 58: Tymlos Phase III trial data in osteoporosis
  • 200 Table 59: Tymlos planned Phase III trials in osteoporosis
  • 208 Table 60: Phase III pipeline products in development for osteoporosis
  • 210 Table 61: Forteo drug profile
  • 212 Table 62: Forteo trial data in osteoporosis
  • 214 Table 63: Late-stage compounds that were recently discontinued for osteoporosis
  • 215 Table 64: Odanacatib drug profile
  • 216 Table 65: Odanacatib trial data in osteoporosis
  • 219 Table 66: Evenity drug profile
  • 221 Table 67: Evenity pivotal trial data in osteoporosis
  • 222 Table 68: Evenity other late-phase trials in osteoporosis
Back to Top